SUMMARY, EXPLANATION AND LIMITATIONS:
VEGF (vascular endothelial growth factor) is a sub-family of growth factors, more specifically of platelet-derived growth factor family of cystine-knot growth factors. Is a homodimeric, disulfide-linked glycoprotein involved in angiogenesis which promotes tumor progression and metastasis. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
VEGF is a dimeric glycoprotein with structural homology to PDGF (platelet derived growth factor). Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo because the expression pattern of VEGF is consistent with a role in embryonic angiogenesis. VEGF mRNA is formed in some primary tumors, VEGF is produced by tumor cell lines in vitro and VEGF mitogenic activity appears to be restricted to endothelial cells. A member of the PDGF receptor family, Flt, has been identified as a high-affinity receptor for VEGF. In certain cancers, high VEGF expression has been correlated with shorter survival and this provides a valuable prognostic marker.
Immunogen: A synthetic peptide derived from C-terminal of human VEGF.
Staining pattern: Cytoplasmic, and cell surface in endothelial cells.
Positive control: Tissue sample from tonsil or angiosarcoma.
This antibody is designed for the specific localization of human VEGF using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.